[go: up one dir, main page]

AR119207A1 - DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR - Google Patents

DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Info

Publication number
AR119207A1
AR119207A1 ARP200101746A ARP200101746A AR119207A1 AR 119207 A1 AR119207 A1 AR 119207A1 AR P200101746 A ARP200101746 A AR P200101746A AR P200101746 A ARP200101746 A AR P200101746A AR 119207 A1 AR119207 A1 AR 119207A1
Authority
AR
Argentina
Prior art keywords
pyrrolo
imidazole derivatives
egfr inhibitors
egfr
imidazole
Prior art date
Application number
ARP200101746A
Other languages
English (en)
Inventor
Cosimo Dolente
Annick Goergler
David Stephen Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Roger David Norcross
Christa Ulrike Obst-Sander
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR119207A1 publication Critical patent/AR119207A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Compuestos derivados de pirrolo[1,2-c]imidazol con actividad inhibitoria alostérica de EGFR, composición farmacéutica que los comprende y su uso en el tratamiento del cáncer de pulmón de células pequeñas. Reivindicación 1: Un compuesto de fórmula (1) o sales farmacéuticamente aceptables.
ARP200101746A 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR AR119207A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181772 2019-06-21

Publications (1)

Publication Number Publication Date
AR119207A1 true AR119207A1 (es) 2021-12-01

Family

ID=67001684

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP200101746A AR119207A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
ARP200101744A AR121167A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200101744A AR121167A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Country Status (20)

Country Link
US (2) US20220315591A1 (es)
EP (2) EP3986567B1 (es)
JP (2) JP7530390B2 (es)
KR (1) KR20220024096A (es)
CN (2) CN113993590B (es)
AR (2) AR119207A1 (es)
AU (1) AU2020296933A1 (es)
BR (1) BR112021024810A2 (es)
CA (1) CA3139171A1 (es)
CL (1) CL2021003373A1 (es)
CO (1) CO2021016967A2 (es)
CR (1) CR20210614A (es)
IL (1) IL287806A (es)
MA (1) MA56507A (es)
MX (1) MX2021015889A (es)
PE (1) PE20220807A1 (es)
PH (1) PH12021553018A1 (es)
TW (2) TW202115070A (es)
WO (2) WO2020254547A1 (es)
ZA (1) ZA202108775B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113993873B (zh) * 2019-06-21 2024-08-02 豪夫迈·罗氏有限公司 用于治疗癌症的egfr抑制剂
TW202115070A (zh) * 2019-06-21 2021-04-16 瑞士商赫孚孟拉羅股份公司 新穎的egfr抑制劑
JOP20220107A1 (ar) 2019-11-11 2023-01-30 Dana Farber Cancer Inst Inc مثبطات egfr تفارغية وطرق استخدامها
CR20230218A (es) * 2020-12-01 2023-07-07 Hoffmann La Roche Nuevos derivados de indazol acetileno
CR20250458A (es) 2023-03-30 2025-11-21 Revolution Medicines Inc Composiciones para inducir la hidrólisis de ras gtp y sus usos
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307365B1 (en) 2008-06-25 2013-03-27 Merck Sharp & Dohme Corp. Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
BR112017024481B1 (pt) 2015-05-14 2020-11-17 The Wistar Institute Of Anatomy And Biology composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo
EP3317273B1 (en) * 2015-06-30 2021-12-29 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
MA53003A (fr) * 2018-06-29 2021-05-05 Hoffmann La Roche Composés
EP3986565B1 (en) 2019-06-21 2023-08-30 F. Hoffmann-La Roche AG New egfr inhibitors
CN113993873B (zh) * 2019-06-21 2024-08-02 豪夫迈·罗氏有限公司 用于治疗癌症的egfr抑制剂
TW202115070A (zh) * 2019-06-21 2021-04-16 瑞士商赫孚孟拉羅股份公司 新穎的egfr抑制劑

Also Published As

Publication number Publication date
JP7530390B2 (ja) 2024-08-07
CA3139171A1 (en) 2020-12-24
TW202115070A (zh) 2021-04-16
US20220112199A1 (en) 2022-04-14
CO2021016967A2 (es) 2022-01-17
KR20220024096A (ko) 2022-03-03
CR20210614A (es) 2022-02-11
WO2020254547A1 (en) 2020-12-24
CN113993591A (zh) 2022-01-28
CN113993590B (zh) 2024-08-23
CN113993590A (zh) 2022-01-28
WO2020254546A1 (en) 2020-12-24
MA56507A (fr) 2022-04-27
IL287806A (en) 2022-01-01
AU2020296933A1 (en) 2021-12-02
PH12021553018A1 (en) 2023-08-23
EP3986567C0 (en) 2023-08-30
BR112021024810A2 (pt) 2022-01-25
TW202115073A (zh) 2021-04-16
CL2021003373A1 (es) 2022-10-07
JP2022537772A (ja) 2022-08-29
US20220315591A1 (en) 2022-10-06
MX2021015889A (es) 2022-02-03
JP2022537771A (ja) 2022-08-29
EP3986567A1 (en) 2022-04-27
EP3986566C0 (en) 2023-08-30
PE20220807A1 (es) 2022-05-20
JP7561779B2 (ja) 2024-10-04
AR121167A1 (es) 2022-04-27
ZA202108775B (en) 2022-09-28
EP3986567B1 (en) 2023-08-30
EP3986566B1 (en) 2023-08-30
EP3986566A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
AR119206A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PH12020551332A1 (en) Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
BR112021019643A2 (pt) Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos
CO2021009879A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
GEAP202215630A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
PH12022550470A1 (en) Triazolopyrimidines as a2a / a2b inhibitors
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
DOP2019000184A (es) Inhibidores selectivos de jak1
BR112021019629A2 (pt) Derivado de espiro que contém nitrogênio como inibidor de ret
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
BR112021017620A2 (pt) Compostos macrocíclicos
ZA202105353B (en) Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
MX2022004713A (es) Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos.
MX2021011979A (es) Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa.
EA202092016A1 (ru) Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2a/a2b
BR112018015501A2 (pt) derivados de pirazolo[1,5-a]pirazin-4-ila como inibidores de jak

Legal Events

Date Code Title Description
FA Abandonment or withdrawal